UA72890C2 - A crystalline form of osanetant (variants), a method for the preparation thereof (variants) and a pharmaceutical composition - Google Patents

A crystalline form of osanetant (variants), a method for the preparation thereof (variants) and a pharmaceutical composition

Info

Publication number
UA72890C2
UA72890C2 UA2001010591A UA2001010591A UA72890C2 UA 72890 C2 UA72890 C2 UA 72890C2 UA 2001010591 A UA2001010591 A UA 2001010591A UA 2001010591 A UA2001010591 A UA 2001010591A UA 72890 C2 UA72890 C2 UA 72890C2
Authority
UA
Ukraine
Prior art keywords
variants
osanetant
preparation
pharmaceutical composition
crystalline form
Prior art date
Application number
UA2001010591A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UA72890C2 publication Critical patent/UA72890C2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UA2001010591A 1998-08-05 1999-08-03 A crystalline form of osanetant (variants), a method for the preparation thereof (variants) and a pharmaceutical composition UA72890C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9810107A FR2782082B3 (fr) 1998-08-05 1998-08-05 Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
PCT/FR1999/001914 WO2000007987A1 (fr) 1998-08-05 1999-08-03 Formes cristallines du osanetant

Publications (1)

Publication Number Publication Date
UA72890C2 true UA72890C2 (en) 2005-05-16

Family

ID=9529458

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001010591A UA72890C2 (en) 1998-08-05 1999-08-03 A crystalline form of osanetant (variants), a method for the preparation thereof (variants) and a pharmaceutical composition

Country Status (32)

Country Link
US (1) US7041679B2 (es)
EP (1) EP1102747B1 (es)
JP (1) JP3807938B2 (es)
KR (1) KR100571944B1 (es)
CN (1) CN1114592C (es)
AR (1) AR019953A1 (es)
AT (1) ATE243197T1 (es)
AU (1) AU748177B2 (es)
BR (1) BR9913357A (es)
CA (1) CA2339007A1 (es)
CO (1) CO5070576A1 (es)
DE (1) DE69908951T2 (es)
DK (1) DK1102747T3 (es)
DZ (1) DZ3074A1 (es)
EA (1) EA003205B1 (es)
EE (1) EE04274B1 (es)
ES (1) ES2200535T3 (es)
FR (1) FR2782082B3 (es)
HK (1) HK1035535A1 (es)
HU (1) HUP0103134A3 (es)
IS (1) IS5821A (es)
MY (1) MY121447A (es)
NO (1) NO320645B1 (es)
NZ (1) NZ509561A (es)
PL (1) PL345999A1 (es)
PT (1) PT1102747E (es)
SK (1) SK1742001A3 (es)
TR (1) TR200100261T2 (es)
TW (1) TW527354B (es)
UA (1) UA72890C2 (es)
WO (1) WO2000007987A1 (es)
YU (1) YU8601A (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
US7648992B2 (en) * 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
TW200800954A (en) * 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
TW202317533A (zh) * 2021-07-02 2023-05-01 美商雅斯治療公司 奧沙奈坦(osanetant)之固體形式

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
EP0915849A2 (en) * 1996-08-05 1999-05-19 Smithkline Beecham S.p.A. Process for the preparation of 3,3-disubstituted piperidines
US6040316A (en) * 1996-09-16 2000-03-21 Warner-Lambert Company 3-alkyl-3-phenyl-piperidines
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Also Published As

Publication number Publication date
TR200100261T2 (tr) 2001-06-21
NO20010553L (no) 2001-04-05
SK1742001A3 (en) 2001-11-06
HUP0103134A2 (en) 2002-06-29
KR100571944B1 (ko) 2006-04-18
ES2200535T3 (es) 2004-03-01
EA200100096A1 (ru) 2001-08-27
CO5070576A1 (es) 2001-08-28
IS5821A (is) 2001-01-23
HK1035535A1 (en) 2001-11-30
PL345999A1 (en) 2002-01-14
WO2000007987A1 (fr) 2000-02-17
PT1102747E (pt) 2003-09-30
DE69908951T2 (de) 2004-05-19
CA2339007A1 (en) 2000-02-17
EA003205B1 (ru) 2003-02-27
AU748177B2 (en) 2002-05-30
NO320645B1 (no) 2006-01-09
EP1102747B1 (fr) 2003-06-18
EP1102747A1 (fr) 2001-05-30
US20040044215A1 (en) 2004-03-04
JP3807938B2 (ja) 2006-08-09
EE200100070A (et) 2002-06-17
AU5168599A (en) 2000-02-28
KR20010072220A (ko) 2001-07-31
DE69908951D1 (de) 2003-07-24
FR2782082B3 (fr) 2000-09-22
DK1102747T3 (da) 2003-09-29
TW527354B (en) 2003-04-11
YU8601A (sh) 2003-07-07
US7041679B2 (en) 2006-05-09
BR9913357A (pt) 2001-05-15
NO20010553D0 (no) 2001-02-01
DZ3074A1 (fr) 2004-07-20
NZ509561A (en) 2002-10-25
FR2782082A1 (fr) 2000-02-11
ATE243197T1 (de) 2003-07-15
CN1314888A (zh) 2001-09-26
AR019953A1 (es) 2002-03-27
JP2002522419A (ja) 2002-07-23
MY121447A (en) 2006-01-28
EE04274B1 (et) 2004-04-15
HUP0103134A3 (en) 2003-03-28
CN1114592C (zh) 2003-07-16

Similar Documents

Publication Publication Date Title
IL111960A (en) Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
HUP9701281A2 (en) Piperidine derivatives as neurokinin antagonists and pharmaceutical compositions containing them
UA72890C2 (en) A crystalline form of osanetant (variants), a method for the preparation thereof (variants) and a pharmaceutical composition
HUP0900417A3 (en) Polymorphs of donepezil hydrochloride and process for production and pharmaceutical compositions containing them
CA2200356A1 (en) Process for preparing levobupivacaine and analogues thereof
RS51824B (en) PHARMACEUTICAL FORMULATION WITH STABILIZED AMORPHIC FORM OF DONEPESIL HYDROCHLORIDE
HUT63384A (en) Process for producing new 1,2,3,6-tetrahydropyridine and piperidine derivatives substituted with n-(hydroxylalkyl) group and compositions comprising such compounds
HUP0401163A3 (en) L crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation and pharmaceutical compositions containing the crystalline forms
NO990721L (no) Stabil ikke-hygroskopisk krystallinsk form av N-[N-N-(4-(piperidin-4-yl)butanoyl)-N-etylglysyl]forbindelser
HUP0100098A2 (hu) Hatóanyagokként, különösen tetrahidro-piridinek és acetil-kolin-észteráz gátlók kombinációját tartalmazó öregkori dementia, különösen Alzheimer típusú dementia kezelésére szolgáló gyógyszerkészítmények
MY118015A (en) Method of crystallizing a tetrahydropyridine derivative and crystalline forms thereby obtained
HUP0105466A3 (en) Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride and pharmaceutical compositions containing them
ZM9486A1 (en) Novel x,x-diaryl-4-aryl-4-hydroxy-l-piperidinebutanamide n-oxides
HU912469D0 (en) Process for producing piperidine derivatives acting as inhibitor during synthesis of cholesterol
RU99115083A (ru) 1-фенилалкил-1,2,3,6-тетрагидропиридины для лечения болезни альцгеймера
UA66776C2 (uk) Форма похідного тетрагідропіридину у вигляді мікрочастинок
BRPI0410934A (pt) método para a produção de chocolate, e, chocolate
HUP0302910A3 (en) Process for the racemisation of 1-benzyl-4-(4-fluorophenyl)-3-hydroxymethyl-1,2,3,6-tetrahydropyridine to be used as intermediate in the synthesis of paroxetine
MY117156A (en) Pharmaceutical composition for oral administration
ZA9711583B (en) Process for the preparation of a tetrahydropyridine derivative.
HUP9902445A2 (hu) Pirrolidin-, piperidin- és hexahidro-azepinkarboxamid-származékok, valamint ezeket a vegyületeket tartalmazó trombózisos rendellenességek kezelésére alkalmas gyógyászati készítmények